With 20 peer-reviewed publications and over 60 abstracts and presentations, Signatera has been incorporated into a growing number of ongoing clinical trials and pharma partnerships, including for registrational studies with potential for CDx development.
Learn about the latest advances in leveraging bespoke ctDNA testing in clinical trials and discover improvements to clinical trial design with Signatera including stratifying and enriching for patients at the highest risk of recurrence and most likely to respond to therapy for clinical enrollment. Additionally, treatment response monitoring can enable the prediction of clinical outcomes as early as 6 weeks into treatment, unlock use as a surrogate endpoint, and accelerate clinical development.
Dr. Angel Augusto Rodriguez is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.
Dr. Simmons leads oncology biopharma partnerships at Natera. He received his Bachelor of Science degree in Biology at American University, graduating with Honors. Dr Simmons earned his PhD in Tumor Biology from Georgetown University. Before joining Natera, he completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx).
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.